Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib Dose Comparison in Hormone Refractory Prostate Cancer
NCT02182063Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2005
- Primary completion
- Jan 2007
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 2, randomised, open-label trial of nintedanib in prostate cancer (PCa) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Decline of prostate specific antigen (PSA) of >=20%. Started Nov 2005; status: completed.
02
Drugs
nintedanib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02182063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182063.